### ACCEPTED MANUSCRIPT • OPEN ACCESS

# Increased breath naphthalene in children with asthma and wheeze of the All Age Asthma Cohort (ALLIANCE)

To cite this article before publication: Pedram Shahrokny et al 2023 J. Breath Res. in press https://doi.org/10.1088/1752-7163/acf23e

## Manuscript version: Accepted Manuscript

Accepted Manuscript is "the version of the article accepted for publication including all changes made as a result of the peer review process, and which may also include the addition to the article by IOP Publishing of a header, an article ID, a cover sheet and/or an 'Accepted Manuscript' watermark, but excluding any other editing, typesetting or other changes made by IOP Publishing and/or its licensors"

This Accepted Manuscript is © 2023 The Author(s). Published by IOP Publishing Ltd.



As the Version of Record of this article is going to be / has been published on a gold open access basis under a CC BY 4.0 licence, this Accepted Manuscript is available for reuse under a CC BY 4.0 licence immediately.

Everyone is permitted to use all or part of the original content in this article, provided that they adhere to all the terms of the licence <a href="https://creativecommons.org/licences/by/4.0">https://creativecommons.org/licences/by/4.0</a>

Although reasonable endeavours have been taken to obtain all necessary permissions from third parties to include their copyrighted content within this article, their full citation and copyright line may not be present in this Accepted Manuscript version. Before using any content from this article, please refer to the Version of Record on IOPscience once published for full citation and copyright details, as permissions may be required. All third party content is fully copyright protected and is not published on a gold open access basis under a CC BY licence, unless that is specifically stated in the figure caption in the Version of Record.

View the article online for updates and enhancements.

2		
3 ⊿	1	Increased breath naphthalene in children with asthma and wheeze of
4 5	2	the All Age Asthma Cohort (ALLIANCE)
6	2	the All Age Astillia Cohort (ALLIANCE)
7	3	P Shahrokny <sup>1,*</sup> . N Maison <sup>2,3,*</sup> . L Riemann <sup>4,5,6</sup> . M Ehrmann <sup>2</sup> . D DeLuca <sup>4</sup> . S Schuchardt <sup>7</sup> . D Thiele <sup>8</sup> .
8	4	M Weckmann <sup>8,9</sup> , AM Dittrich <sup>4</sup> , B Schaub <sup>2</sup> , F Brinkmann <sup>8</sup> , G Hansen <sup>4</sup> , MV Kopp <sup>10</sup> , F von
9 10	5	Mutius <sup>2,3</sup> KE Rabe <sup>11</sup> T Rahmer <sup>11,12</sup> IM Hohlfeld <sup>1,13</sup> R Gruchtol <sup>4,*</sup> O Holz <sup>1,*</sup> and the Alliance
11	5	study group
12	0	study group
13	7	*contributed equally
14	~	
16	8	<sup>2</sup> Fraunnoter HEIM, Department of Clinical Airway Research, German Center for Lung
17	9	Research (BREATH, DZL), Hannover, Germany
18	10	<sup>2</sup> Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University, German Center for
19 20	11	Lung Research (CPC-M, DZL), Munich, Germany
20	12	<sup>3</sup> Institute of Asthma and Allergy Prevention, Heimholtz Zentrum Munchen, German
22	13	Research Center for Environmental Health, Neuherberg, Germany
23	14	* Department of Paediatric Pneumology, Allergology and Neonatology, Hannover Medical
24 25	15	School, German Center for Lung Research (BREATH, DZL), Hannover, Germany
25 26	16	<sup>3</sup> Clinician Scientist Program IIIUS, Else-Kroner-Fresenius-Stiftung, Hannover Medical School,
27	17	Hannover, Germany
28	18	<sup>o</sup> Institute of Immunology, Hannover Medical School, Hannover, Germany
29	19	<sup>2</sup> Fraunhofer ITEM, Bio- and Environmental Analytics, Hannover, Germany
30 21	20	<sup>o</sup> Division of Pediatric Pulmonology and Allergology, University Children's Hospital, German
31	21	Center for Lung Research (ARCN, DZL), Luebeck, Germany
33	22	<sup>9</sup> Epigenetics of Chronic Lung Disease, Priority Research Area Chronic Lung Diseases, Leibniz
34	23	Lung Research Center Borstel, Borstel, Germany
35	24	<sup>10</sup> Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern,
36 27	25	Switzerland
38	26	<sup>11</sup> LungenClinic Grosshansdorf and Department of Medicine, Christian-Albrechts-University
39	27	Kiel, German Center for Lung Research (ARCN, DZL), Grosshansdorf, Germany
40	28	<sup>12</sup> Pulmonary Research Institute at LungenClinic Grosshansdorf, German Center for Lung
41	29	Research (ARCN, DZL), Grosshansdorf, Germany,
42 43	30	<sup>13</sup> Department of Respiratory Medicine, Hannover Medical School (MHH), Hannover, Germany
44	31	
45	32	Funding: German Center for Lung Research (DZL), Else-Kröner-Fresenius-Stiftung
46	33	Wordcount: 35//
47	55	Wordcount. 3344
48 49	34	Revised Version 18.07.23
50		
51	35	Corresponding author:
52		
53 54	36	Prof. Dr. JM Hohlfeld
54 55	37	Department of Clinical Airway Research,
56	38	Fraunhofer Institute for Toxicology and Experimental Medicine,
57	39	30625 Hannover, Germany
58	40	Phone: +49-511-5350-8101
59 60	41	Fax: +49-511-5350-8250
00	42	jens.hohlfeld@item.fraunhofer.de

#### Abstract

Background

Exhaled breath contains numerous volatile organic compounds (VOCs) known to be related to lung disease like asthma. Its collection is non-invasive, simple to perform and therefore an attractive method for the use even in young children. We analysed breath in children of the multicenter All Age Asthma Cohort (ALLIANCE) to evaluate if "breathomics" have the potential to phenotype patients with asthma and wheeze, and to identify extrinsic risk factors for underlying disease mechanisms. 

Methods

A breath sample was collected from 142 children (asthma: 51, pre-school wheezers: 55, healthy controls: 36) and analysed using gas chromatography-mass spectrometry (GC/MS). Children were diagnosed according to GINA guidelines and comprehensively examined each year over up to seven years. Forty children repeated the breath collection after 24 or 48 months. 

Results 

Most breath VOCs differing between groups reflect the exposome of the children. We observed lower levels of lifestyle-related VOCs and higher levels of the environmental pollutants, especially naphthalene, in children with asthma or wheeze. Naphthalene was also higher in symptomatic patients and in wheezers with recent inhaled corticosteroid use. No relationships with lung function or TH2 inflammation were detected. 

Conclusion

Increased levels of naphthalene in asthmatics and wheezers and the relationship to disease severity could indicate a role of environmental or indoor air pollution for the development or progress of asthma. Breath VOCs might help to elucidate the role of the exposome for the development of asthma.

- The study was registered at ClinicalTrials.gov (NCT02496468).
  - Word count: 235

Key words: exhaled air, VOC, pediatric asthma, wheeze, ALLIANCE 

# 75 Introduction

Asthma is one of the most prevalent pediatric chronic diseases worldwide and causes significant burden on patients, family, society and healthcare systems [1–3]. Characteristic clinical features are chronic airway inflammation and variable expiratory airflow obstruction presenting as cough, wheeze, chest tightness and dyspnea usually in response to specific triggers, e.g. viral infections and exposure to allergens [4].

Despite similar clinical manifestation, the pathobiology and course of the disease is very heterogeneous [5]. Many factors contribute to asthma development, among them genetics, epigenetics [6], prenatal influences as maternal smoking, viral respiratory tract infections in early life [7] and unfavorable environmental exposures to cigarette smoke, air pollution, allergens, or mold [8, 9]. There is particular need for non-invasive and simple to assess biomarkers for early disease detection and characterization, especially in children. While exhaled nitric oxide is considered as an established non-invasively accessible biomarker [10, 11], it mainly reflects the level of eosinophilic airway inflammation. For a more comprehensive analysis, volatile organic compounds (VOC) in exhaled breath have gained considerable interest as biomarkers for lung diseases, especially in asthma [12–14].

Breath collection is non-invasive and only requires tidal breathing which makes it particularly attractive for the use in children even at a young age. A number of studies on breath VOCs in adult and pediatric asthma have been published in the last decade and are considered in recent reviews [12–14]. For example, Dallinga et al. showed that exhaled VOCs can distinguish asthmatic from non-asthmatic children [15], and there is evidence that breath VOCs identify distinct inflammation phenotypes [16] or predict exacerbations in asthmatic children [17, 18]. Despite a large body of literature with a number of VOCs potentially discriminating between healthy controls and asthma patients or reflecting disease activity or treatment, there is currently no breath VOC biomarker or biomarker pattern that supports physicians in the diagnosis, treatment, and phenotyping of disease or in preventing exacerbations.

Here, we collected and analyzed breath VOCs from a subgroup of children of the All Age Asthma cohort (ALLIANCE), a multicenter prospective observational cohort recruiting children with pre-school wheeze and children and adults with asthma [19].

We hypothesized that VOCs or VOC patterns are distinct between children with asthma or pre school wheeze compared to healthy children and contribute to identify extrinsic risk factors,
 and underlying disease mechanisms. Additionally, we investigated if VOCs were linked to

107 inflammatory phenotypes, clinical features such as lung function, asthma treatment and108 exacerbation rate.

109 Methods

110 Study design

The ALLIANCE cohort of the German Center for Lung Research (DZL) is a prospective multicenter asthma cohort [19]. For this study, we collected 182 breath samples from 142 children (51 children with asthma, 55 children with wheeze and 36 healthy controls) at two pediatric specialist centers (Hannover, Munich) from October 2016 until spring 2020 (figure 1, table S1). In a subgroup of 40 patients, a second breath collection was performed after one or two years (asthma n=20, wheeze n=20). The study was conducted in accordance with the principles embodied in the Declaration of Helsinki and in accordance with local statutory requirements. The study was registered at ClinicalTrials.gov (NCT02496468) and approved by all local ethics committees. All parents of study participants <18 years as well as study participants  $\geq 8$  years gave their written informed consent. 

Children aged 6 months to 5 years were included if they had at least two episodes of wheeze during the past 12 months ('pre-school wheezer') as indicated by the parents in the respective questionnaire. Children ≥6 years were included based on doctor-diagnosed asthma according to the Global Initiative for Asthma (GINA) guidelines and German guidelines [4, 20]. We also recruited healthy control subjects who had never been diagnosed with asthma or pre-school wheeze. Further inclusion and exclusion criteria are specified in the supplement or have been published [19]. Laboratory tests included differential blood count, and specific immunoglobulin E against 36 allergens measured by Euroline<sup>™</sup> (Euroimmun, Germany). All children performed exhaled nitric oxide (FeNO) measurements and spirometry from age 4 years onwards and VOC measurements from 3 years onwards. For the breath and near-subject room air collection we used an in-house developed breath collection device [21]. Further details regarding all procedures and study design are presented in the **online supplement**. 

51 133

<sup>52</sup> <sub>53</sub> 134 Analysis by gas chromatography-mass spectrometry (GC-MS)

GC-analysis of the samples was performed at Fraunhofer ITEM, Hannover, within eight days
 of initial breath collection. Turbo Mass Software 5.4 (PerkinElmer, USA) was used for
 automated identification of individual VOCs based on retention time of specific masses,
 comparing values with reference compounds and the NIST database (National Institute of

Standards and Technology Mass Spectral Search Program Version 2.2 (NIST, USA)) [21, 22]. A total of 158 VOCs were quantified using peak height of specific target ions which most commonly matched with m/z signals of highest intensity in the respective VOC mass spectrum (total Ion content (TIC)) [22]. Further details regarding measurement and analysis are available 

143 in the **online supplement**.

13 144 *Statistics* 

We computed the mean value of the 158 target VOCs for all technical replicate samples. Data was then log-transformed. We used the Mann-Whitney-U-Test (MWU) for univariate comparisons between patients (asthma, wheeze) and healthy controls and the Pearson correlation coefficient where appropriate. The false discovery rate was assessed by correcting raw p-values with the *p.adjust* function in R (using the Benjamini and Hochberg (BH) option). Corrected p-values are indicated as pBH. Site effects were accounted for by batch correction using the ComBat function of the R package sva to our data. For some analyses that were limited to data from one site we used both the original (uncorrected) and the batch corrected "site-effect-free data" to test whether similar results were obtained. 

Due to the exploratory nature of our analysis, we focused on the complete VOC dataset (n=158 VOCs). However, to avoid missing important observations by the multiplicity correction we also ran the analysis with subsets of our 158 VOCs. A detailed description of these subsets is provided in the online supplement. In addition we dimensionally reduced the dataset using an unsupervised clustering approach called Cytomod [23]. Briefly, VOCs were clustered and assigned to co-varying modules based on the pairwise Pearson-correlations between log-transformed VOC values. For more details, please refer to the online supplement. Module scores reflecting the expression of each module in each participant (see **online supplement**) were compared between participant groups with different characteristics using MWU tests. P-values were adjusted for the number of modules tested. A multivariable logistic regression model was used to analyze the association between module 6 and disease status. We focused our analysis on module 6, because most VOCs considered as air pollutants were found in module 6. 

#### Results

#### **Demographics**

As shown in **figure 1**, we included 55 children with pre-school wheeze, 51 children with asthma and 36 healthy controls (table 1). Total IgE and FeNO were higher (p<0.01) in asthmatics than in healthy controls while FEV<sub>1</sub> and FEV<sub>1</sub>/FVC values were lower (p<0.01). Blood eosinophils were higher in asthmatic children compared to controls (p=0.01), and atopy was more prevalent in subjects with wheeze and asthma (table 1). 



Figure 1. Study population. Breath VOCs were analyzed from 142 subjects. 40 subjects were sampled on two visits, which were at least one year apart. The Hannover site had a focus on wheezers and started the recruitment for VOC sampling later during the study. The one patient with asthma from Hannover was planned to be included as wheezer but the visit could not be scheduled before the 6<sup>th</sup> birthday, therefore based on the definition criteria, this subject was considered as child with asthma. 

#### Basic data description, quality, and plausibility of VOC data

As expected, acetone and isoprene were major VOCs in breath of children, while disinfectants like 1-propanol, 2-propanol, ethanol, 2-phenoxyethanol, and 1-phenoxypropan-2-ol were the major VOCs detected in the room air samples. In line with the "owncloud concept" [22] we found the expected correlations between near-subject room air and breath for VOCs, that are frequently used in lifestyle products (personal care, cosmetics, home care) or for environmental pollutants. Among these were geranyl acetone, siloxanes, as well as benzene (figure S1). Furthermore, patients exposed to second-hand smoke and in one patient to active smoking showed increased levels of cigarette smoke related VOCs (table S2) [21, 24]. Isoprene

1 2		
3 4	202	levels in exhaled breath significantly correlated with age (r=0.36, p<0.0001), as previously
5	203	shown [25].
7 8 9 10 11 12 13 14 15	204	
	205	Potential confounders: site, age, gender
	206	The median levels of most VOCs were different between study sites. We consider technical
	207	reasons, like instrument drift, as unlikely for this observation (details are presented in the
	208	online supplement) and adjusted the data as outlined in material and methods. To evaluate
15 16 17	209	the impact of age we checked the correlation between VOC values and age using the site
17	210	effect-free data for all subjects. Besides the already mentioned positive isoprene correlation,
19 20	211	we only found a negative correlation for 1,2-propandiol and age (r=-0.27), with borderline
21 22	212	significance (pBH=0.068). No significant gender-specific differences for breath VOCs were
23 24	213	observed (pBH>0.05).
25 26	214	
27	215	Reproducibility between visits
20 29	216	For 40 children (asthma n=20, wheeze n=20) we were able to collect a second sample in a
30 31	217	follow-up visit one year after taking the initial sample. In three cases, the second sample was
32 33	218	taken two years later. Initial and follow-up VOCs values correlated significantly for 13 VOCs
34 35	219	(pBH<0.05, figure S2, table S3). Most of these VOCs appear to be environment- and lifestyle-
36 37	220	related. The correlation between the visits was not significant for naphthalene (figure S3,
38	221	р=0.06, рВН=0.27).
40	222	
41 42	223	Cluster analysis
43 44	224	In the unsupervised cluster analysis, we identified a total of 9 modules (figure 2), consisting of
45 46	225	3 to 39 VOCs. The VOCs contained in each module are listed in the supplement (table S4).
47 48	226	Interestingly, all BTEX (benzene, toluene, ethylbenzene, xylenes) VOCs and other VOCs
49	227	considered as air pollutants, like naphthalene, were found in module 6. A large number of
50 51	228	VOCs in module 4 were substances used as fragrances and flavors typically found in many
52 53	229	lifestyle and cleaning products.
54 55	230	
56 57	231	VOCs differ between children with asthma or pre-school wheeze and healthy controls
58 59	232	We found 24 significantly different VOCs (pBH<0.05) between healthy controls and asthma
60	233	patients and 23 significantly different (pBH<0.05) VOCs between healthy controls and children



Figure 2: Heatmap of VOC modules: VOCs are first clustered together based on pairwise Pearson correlations. A reliability score (i.e., the fraction of times that a given VOC is assigned to the same cluster) is calculated over 1,000 permutations of participants and is used to assign VOCs to modules. The color bars on the left side depict the module membership for each VOC (a full list is given in supplement **table S4**), and the coloring in the heatmap represents the reliability score of each VOC.

with wheeze (table 2). There was a large overlap, with 13 VOCs having significantly different levels both in asthma patients and wheezers compared to healthy controls (table 2). As clinical characteristics differed between healthy controls and patients (table 1), we performed additional subgroup analyses which are described in detail in the online supplement. We did not find any evidence that these differences influenced the results. 

Most of the VOCs with significantly higher levels in breath of healthy controls are used as fragrances or flavors and can therefore be found in lifestyle products and foods (table 2). Some of these VOCs with suspected fragrance or flavor origin correlated among each other, which could indicate common sources (table S5). This result was also mirrored in the cluster analysis data, as most of the VOCs, which were increased in healthy controls, were found in module 4 as indicated in table 2 and figure 2. Module 4 values were also significantly higher in healthy controls compared to asthmatic children (pBH=0.006) and children with wheeze (pBH=0.03), respectively (figure S4). 

Breath naphthalene levels showed the largest difference between children with asthma or wheeze and healthy controls (table 2, figure 3). Furthermore, other VOCs considered as air pollutants, such as 1,2-propanediol and ethylhexanol were also increased in asthma or wheeze. Although not statistically significant (pBH>0.05), we additionally observed higher breath levels for other aromatic air pollutants (table 2). These were significantly correlated (all p<0.01) among each other and with naphthalene (figure S5), again suggesting a common source. All these environmental pollutants were found in module 6 as indicated in table 2. Consistent with this result, overall module 6 values were higher in asthmatic children (pBH=0.07) and children with wheeze (pBH=0.03) compared to healthy controls (figure S4). 



**Figure 3.** Differences in the levels of naphthalene between groups. Median and interquartile ranges. Individual data is shown in grey open circles. \*\*\* p<0.001, \*\* p<0.01.

<sup>49</sup> <sub>50</sub> 294 <u>VOC profiles associated with disease characteristics</u>

VOCs or module 4 and 6 values did not differ depending on presence of atopy, blood eosinophilia, or increased FeNO (see online supplement for definition and further details). Similarly, we did not find any correlations between VOCs and FeNO or absolute blood eosinophil levels. No correlations were found for VOCs or module values and FEV<sub>1</sub> z-score, neither for asthma patients, wheezers or both groups combined. There were also no differences when comparing participants with FEV<sub>1</sub>z-scores <-1 to those with z-scores >-1. The same results were found for the FEV<sub>1</sub>/FVC data. For FEF<sub>25-75</sub> the results were also similar,
except for asthma patients. Here we found higher levels for six VOCs (all in module 4), among
them capric-acid, undecane and undecanal and for module 4 values (pBH<0.05) in asthma</li>
patients with a z-score <-1.</li>

11 305

# 12<br/>13306VOC profiles associated with disease control

No significantly different VOC levels were found between asthmatic children and wheezers with controlled disease according to GINA guideline definition [4] (n=87 and those with "partly-controlled" or "uncontrolled" asthma" (n=19) when testing the different VOC subsets as defined in material and methods (pBH>0.05)). Testing only naphthalene showed significantly higher levels in the partly- and uncontrolled group (p<0.008), which is compatible with the observed trend to increased module 6 values (p=0.03, pBH 0.251). No difference was observed for module 4. 

VOCs or module 4 and 6 values did not differ between children with or without exacerbations or wheeze episodes in the past 12 months. In wheezers with current use of inhalative corticosteroids (ICS), we found significantly higher levels for 1-phenoxypropan-2-ol (pBH=0.03) and for naphthalene (p=0.01). Both are found in module 6, which also showed higher values in this group (pBH=0.06). In addition, higher levels for an unidentified terpene (pBH≤0.008), and three alkanes (undecane, dodecane and decane) were observed (pBH=0.09) Two of these VOCs were found in module 4, which showed a trend for higher module values in this group (pBH=0.06). 

- 42 322
- 44 323

# 323 Association of cluster module 6 with asthma or pre-school wheeze

As VOC module 6 was increased in children with asthma or pre-school wheeze, we were interested in investigating this association while controlling for other known risk factors for asthma development. In a multivariable analysis, increased values for VOC module 6 were significantly associated with asthma and pre-school wheeze, also when adjusting for age, parental asthma, gender, presence of atopy, elevated blood eosinophil counts, and secondary cigarette smoke exposure (table 3). Only atopy was also significantly associated to asthma or wheeze status in our multivariable regression model. 

#### Discussion

In this study, we showed that breath VOCs differ between healthy children and patients with asthma or pre-school wheeze. Most of the differential VOCs were related to the exposome of the patients. Lifestyle-related VOCs were generally lower in children with wheeze or asthma compared to healthy children. More importantly, several air pollutants, especially naphthalene, showed higher breath levels in children with wheeze or asthma. The association between pollutant-related VOCs and asthma or wheeze held true in a multivariable model with adjustment for other known disease risk factors. The most prominent VOC linked to asthma or wheeze was naphthalene, however cluster analysis also identified several other pollutants like benzene, toluene, ethylbenzene, and xylene (BTEX), which were linked to asthma or wheeze. Benzene and ethylbenzene originate mainly from traffic emissions and incomplete combustion, while other BTEX are related to indoor exposure caused by proximity to road traffic, cigarette smoking or cooking methods [26, 27]. In agreement with our results, other authors have also shown increased levels of these VOCs in patients with asthma [28, 29].

Naphthalene is a very volatile polycyclic aromatic hydrocarbon (PAH) predominantly present in the atmosphere in its vapor form [27]. It's a natural constituent in coal tar and oil, and a ubiquitous pollutant in the environment [27]. Large amounts are produced worldwide [30], primarily as an intermediate for other chemicals and airborne emissions originate from incomplete combustion, e.g. in traffic exhaust, during burning of biomass, or tobacco smoke [27]. Inhalation is being considered as the most significant route of exposure [31]. We did not find differences in breath naphthalene levels for children who lived in the proximity of larger roads or who were exposed to environmental tobacco smoke, but this analysis was only based on questionnaire data which is only a crude estimate of the real life exposure. Naphthalene concentrations can also be increased indoors [27], especially in buildings with attached garages or integrated fireplaces [27, 32]. A range of indoor building materials has been reported to emit naphthalene, e.g. caulking, carpeting, rubber or vinyl flooring [33]. Cabins of diesel- and gasoline-fuel cars have also been reported as relevant sources [34]. In our study, we did not have information about these potential exposures. Therefore, it would be interesting for future studies to include personal sampling devices. Diet has also been

described as a potential source of naphthalene [27], however, this contribution will be difficult to control for in cohort studies.

In children with pre-school wheeze, increased breath naphthalene levels have been observed before [35], but its potential role was not further discussed. Increased naphthalene levels have also been reported in blood and urine of children with asthma. In a study comparing PAH levels in 195 children, naphthalene serum levels showed one of the strongest associations with asthma [36], while increased 2-naphthol levels, a naphthalene metabolite, could be found in urine of asthmatic children [37]. Increased PAH metabolite levels in urine of children with asthma were associated with higher disease-specific symptoms and consequently decreased lung function parameters [38]. All substances mentioned above were part of module 6 with considerable correlation among each other, which suggests regular exposure to a potential common source. Little is known so far regarding the potential pathomechanisms linking naphthalene and asthma. Murine studies showed that naphthalene could have local effects on the respiratory epithelium as well as systemic affects due to high plasma concentrations after inhalation [30, 39, 40], however, the exact role in asthma development is still uncertain. 

In contrast to the strong pollution signature in children with asthma and wheeze, we found increased levels of flavor and lifestyle related VOCs in healthy subjects. Although speculative, one possible explanation could be a higher awareness of parents of asthmatic or wheezing children limiting exposure to strong flavorings, cosmetics, or cleaning products while parents of healthy children might be less restrictive. 

Eleven of the compounds found to be different between healthy children and patients (table 2) have been related to asthma in previous studies [13, 14], however the overlap with our results is quite small. Recent reviews show that this is not uncommon in studies with asthma or wheezing patients [12, 13] and very likely due to differences in patient populations and in sampling and analysis methods. Furthermore, as we used a predefined target VOC dataset comprising of 158 VOCs, we might not have detected some of the previously reported VOCs in comparable trials with asthma patients. 

We found no relationships of VOC profiles with clinical characteristics such as asthma control or risk for exacerbations [17, 18]. Similarly, VOCs were not associated with inflammatory 

396 phenotypes, i.e. type 2 inflammation, confirming previous negative results from the adult arm 397 of the ALLIANCE cohort [41]. In this respect it is important to note that about 73 % of the 398 asthmatic children were under anti-inflammatory treatment when the breath collection was 399 performed. We cannot exclude that this has reduced our chance of finding VOC patterns 400 associated with inflammation, however we still observed significantly higher FeNO levels in 401 the asthmatic children, indicating ongoing airway inflammation.

Naphthalene and two other VOCs of module 6 were increased in pre-school wheezers treated with ICS, supporting the proposed link between air pollution as a disease driving factor, as ICS treatment in this age group identifies children with a more severe phenotype. Additionally, children with pre-school wheeze and regular ICS treatment showed higher levels of three different long chain alkanes, which have previously been identified in COPD patients with respiratory tract infections caused by Rhinovirus [42]. This could potentially point towards an inflammatory phenotype driven by recurrent viral infections. However, it needs to be mentioned that one of these alkanes (undecane) was also part of module 4 and increased in healthy controls thus illustrating the complexity of the data and the difficulties in distinguishing exogenous and endogenous sources of VOCs.

A strength of our study is the choice of method for breath collection and VOC analysis which has been benchmarked in a previous trial [43]. Furthermore, our results were in concordance with several expected findings. For example, we were able to identify cigarette smoke related VOCs in children exposed to environmental tobacco smoke, and we saw significant correlations for lifestyle related VOCs between repeated measurements over at least one year. Correlations between near-subject room air and breath for VOCs related to hygiene product and detergents are in line with our "owncloud" concept [22].

It's well known that the VOC composition of breath is influenced by many factors [44], among them demographic, diet, life style and recent activity. Therefore, we interpret the observed correlations of VOCs between the repeated measurements as remarkable, despite rather low correlation coefficients (r≤ 0.6) and consider these as an indication for stable living and lifestyle conditions. 

However, we also have to report some limitations. Our data showed a marked center effect
 Which we had observed in a previous multicenter study as well [24]. All analyses were
 performed using batch-corrected data and original data whenever possible (supplementary

material) and the comparable results indicate that batch correction did not introduce an unwanted bias to our data.

In line with our previous studies [21, 22, 24] we limited our GC-MS analysis to preselected 158 VOCs instead of performing a broad analysis of all potential peaks in a chromatogram. While the latter is likely to include more features for comparison, there is a risk for false identification of VOCs, which coelute at the same retention time. On the downside, by including only preselected VOCs, we cannot exclude to have missed VOCs which could have been relevant for the comparison between groups. Unfortunately, healthy control children were not age-matched to children with asthma or wheeze. However, only two VOCs out of 158 VOCs were actually age dependent, which makes a significant influence of age on the result unlikely. Overall, we focused our analysis on single VOC comparisons as well as the two modules 4 and 6, which comprised most of the significantly different VOCs found in the single VOC analysis. Some other VOCs modules were also significantly different between the study groups, however, further detailed analysis of all modules was beyond the scope of this manuscript. 

In this study, we were able to identify VOCs associated with asthma and pre-school wheeze indicating an increased exposure of these children to environmental pollutants. Due to the observational nature of our study, we cannot deduce a causal relationship of these environmental exposures to the development of asthma. Still, the strong association confirmed in a multivariable analysis as well as the fact that the result was already seen in pre-school wheezers and in the case of naphthalene particularly in those more severely affected supports previous findings that exposure to pollutants might be an early life factor driving asthma pathology [7]. Although we could not find associations between VOCs and clinically relevant features as inflammatory phenotypes or risk for exacerbations, we consider non-invasive breath analysis an interesting tool to assess the exposome of children and to decipher the role of environmental exposures in the development of airway diseases. The increased levels of breath naphthalene and other PAH in asthmatic and wheezing children would be a strong argument to include breath sampling and potentially also personal sampling devices into future studies to better understand the role of environmental and especially indoor air pollutants. 

1		
2 3	460	Acknowledgment
4	400	
5 6	461	We would like to express our gratitude to Manfred Elend († 17.04.21). Without his
7	462	extraordinary experience in GC-MS analysis and his valuable advice, we would not have been
8 9	463	able to collect the data of this study.
10 11 12	464	
12	465	References
14 15	466	[1] Song P, Adeloye D, Salim H, Dos Santos J P, Campbell H, Sheikh A and Rudan I 2022 Global,
15	467	regional, and national prevalence of asthma in 2019: a systematic analysis and modelling study
17	468	Journal of global health <b>12</b> 4052
18	469	[2] Aumann I, Prenzler A, Welte T and Gillissen A 2014 Epidemiologie und Kosten von Asthma
19 20	470	bronchiale in Deutschland - eine systematische Literaturrecherche Pneumologie (Stuttgart,
20 21	471	Germany) <b>68</b> 557–67
22	472	[3] 2020 Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a
23	473	systematic analysis for the Global Burden of Disease Study 2019 Lancet (London, England) 396
24	474	1204–22
25 26	475	[4] GINA Main Report 2022 Front Cover
27	476	[5] Habib N, Pasha M A and Tang D D 2022 Current Understanding of Asthma Pathogenesis and
28	477	Biomarkers Cells 11
29	478	[6] Alashkar Alhamwe B, Alhamdan F, Ruhl A, Potaczek D P and Renz H 2020 The role of epigenetics
30 21	479	in allergy and asthma development <i>Current opinion in allergy and clinical immunology</i> <b>20</b> 48–55
32	480	[7] Bush A 2021 Impact of early life exposures on respiratory disease <i>Paediatric respiratory reviews</i>
33	481	
34	482	[8] Mukharesh L, Phipatanakul W and Gaffin J M 2023 Air pollution and childhood asthma <i>Current</i>
35	483	opinion in allergy and clinical immunology <b>23</b> 100–10
30 37	484	[9] Tiotiu A I, Novakova P, Nedeva D, Chong-Neto H J, Novakova S, Steiropoulos P and Kowal K 2020
38	485	Impact of Air Pollution on Astrima Outcomes International journal of environmental research and
39	486	public nealth 17
40	487	[10] Knatri S B et al Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma: An
41 42	400	official American Thoracic Society Clinical Practice Guideline 2021 American journal of
42	489	Tespiratory and critical care medicine <b>204</b> e97-e109
44	490	of asthma in childran aged 5.16 years. The Euronean respiratory journal <b>59</b>
45	491 100	[12] Ibrahim W. Natarajan S. Wilde M. Cordell P. Monks D.S. Greening N. Brightling C.E. Evons P. and
46	492 102	Siddigui S 2021 A systematic review of the diagnostic accuracy of volatile organic compounds in
47 48	495	siduldul 3 2021 A systematic review of the diagnostic accuracy of volatile organic compounds in
49	494	[12] Peel A M. Wilkinson M. Sinha A. Loke V.K. Fowler S. Land Wilson A M 2020 Volatile organic
50	495	compounds associated with diagnosis and disease characteristics in asthma - A systematic
51	450	review Respiratory medicine 169 105984
52 53	497	[14] Neerincy A H. Viiverberg S I H. Bos I D I. Brinkman P. van der Schee M.P. Vries R de. Sterk P. Land
54	490	Maitland-van der Zee A-H 2017 Breathomics from exhaled volatile organic compounds in
55	500	nediatric asthma Pediatric nulmonology 52 1616–27
56	501	[15] Dallinga I W. Robroeks C M H H T. van Berkel I I B N. Moonen F I C. Godschalk R W I. Jöbsis O
5/ 52	502	Dompeling E. Wouters E F M and van Schooten F I 2010 Volatile organic compounds in exhaled
50 59	503	breath as a diagnostic tool for asthma in children <i>Clinical and experimental alleray</i> : iournal of
60	504	the British Society for Allergy and Clinical Immunology <b>40</b> 68–76
		15

1			
2	FOF	[4 ]	Cablaich E N et al 2010 Eule di Valatila Oraș aia Camara un da Ara Abla ta Disarinaire ta batura an
4	505	[16]	Schleich F N et al 2019 Exhaled Volatile Organic Compounds Are Able to Discriminate between
5	506		Neutrophilic and Eosinophilic Astrima American Journal of respiratory and critical care medicine
6	507	[4 -7]	
7	508	[17]	Robroeks C M, van Berkel J J, Jobsis Q, van Schooten F-J, Dallinga J W, Wouters E F and
8	509		Dompeling E 2013 Exhaled volatile organic compounds predict exacerbations of childhood
10	510	[ 4 0 ]	asthma in a 1-year prospective study The European respiratory journal 42 98–106
11	511	[18]	Olopade C.O., Zakkar M, Swedler W I and Rubinstein I 1997 Exhaled pentane levels in acute
12	512	[ 4 0 ]	asthma Chest 111 862–5
13	513	[19]	Fuchs O et al 2018 The all age asthma cohort (ALLIANCE) - from early beginnings to chronic
14 15	514		disease: a longitudinal cohort study BMC pulmonary medicine <b>18</b> 140
15 16	515	[20]	Bundesärztekammer (BAK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der
17	516		Wissenschaftlichen Medizinischen Fachgesellschaften 2020 Nationale VersorgungsLeitlinie
18	517		Asthma – Langfassung www.asthma.versorgungsleitlinien.de
19	518	[21]	Küppers L, Holz O, Schuchardt S, Gottlieb J, Fuge J, Greer M and Hohlfeld J M 2018 Breath
20	519		volatile organic compounds of lung transplant recipients with and without chronic lung allograft
21	520		dysfunction <i>Journal of breath research</i> <b>12</b> 36023
23	521	[22]	Holz O, van Vorstenbosch R, Guenther F, Schuchardt S, Trinkmann F, van Schooten F-J, Smolinska
24	522		A and Hohlfeld J M 2022 Changes of breath volatile organic compounds in healthy volunteers
25	523		following segmental and inhalation endotoxin challenge Journal of breath research 16
26	524	[23]	Cohen L et al 2019 A Modular Cytokine Analysis Method Reveals Novel Associations With Clinical
27	525		Phenotypes and Identifies Sets of Co-signaling Cytokines Across Influenza Natural Infection
29	526		Cohorts and Healthy Controls Frontiers in Immunology 10
30	527	[24]	Gaida A et al 2016 A dual center study to compare breath volatile organic compounds from
31	528		smokers and non-smokers with and without COPD Journal of breath research 10 26006
32	529	[25]	Lechner M, Moser B, Niederseer D, Karlseder A, Holzknecht B, Fuchs M, Colvin S, Tilg H and
33 34	530		Rieder J 2006 Gender and age specific differences in exhaled isoprene levels Respiratory
35	531		physiology & neurobiology <b>154</b> 478–83
36	532	[26]	Vardoulakis S, Giagloglou E, Steinle S, Davis A, Sleeuwenhoek A, Galea K S, Dixon K and Crawford
37	533		J 2021 Indoor Exposure to Selected Air Pollutants in the Home Environment: A Systematic Review
38	534	[27]	Jia C and Batterman S 2010 A critical review of naphthalene sources and exposures relevant to
39 40	535		indoor and outdoor air International journal of environmental research and public health <b>7</b>
41	536		2903–39
42	537	[28]	Gahleitner F, Guallar-Hoyas C, Beardsmore C S, Pandya H C and Thomas C P 2013 Metabolomics
43	538		pilot study to identify volatile organic compound markers of childhood asthma in exhaled breath
44 45	539		Bioanalysis <b>5</b> 2239–47
45 46	540	[29]	Arif A A and Shah S M 2007 Association between personal exposure to volatile organic
47	541		compounds and asthma among US adult population International archives of occupational and
48	542		environmental health <b>80</b> 711–9
49	543	[30]	Yost E E, Galizia A, Kapraun D F, Persad A S, Vulimiri S V, Angrish M, Lee J S and Druwe I L 2021
50 51	544		Health Effects of Naphthalene Exposure: A Systematic Evidence Map and Analysis of Potential
52	545		Considerations for Dose-Response Evaluation Environmental health perspectives 129 76002
53	546	[31]	Preuss R, Angerer J and Drexler H 2003 Naphthalenean environmental and occupational
54	547		toxicant International archives of occupational and environmental health <b>76</b> 556–76
55	548	[32]	Hoffmann K, Krause C, Seifert B and Ullrich D 2000 The German Environmental Survey 1990/92
56	549		(GerES II): sources of personal exposure to volatile organic compounds Journal of exposure
57 58	550		analysis and environmental epidemiology <b>10</b> 115–25
59			
60		7	
			4
		V	16

2		
3	551	[33] Kang D H, Choi D H, Won D, Yang W, Schleibinger H and David J 2012 Household materials as
4	552	emission sources of naphthalene in Canadian homes and their contribution to indoor air
5	553	Atmospheric Environment <b>50</b> 79–87
0 7	554	[34] Jo W-K and Lee J-H 2009 In-Vehicle Levels of Naphthalene and Monocyclic Aromatic Compounds
, 8	555	According to Vehicle Type Environmental Engineering Research <b>14</b> 180–5
9	556	[35] van de Kant K D G <i>et al</i> 2013 Exhaled breath profiling in diagnosing wheezy preschool children
10	550	The European receivatory journal <b>41</b> 192. 9
11	557	[2C] AL Deskri N.M. Aleksi M.C. And Alekemen C.H. Dres U.M. Vekeut C.M. and Clerini M. 2012
12	558	[36] Al-Dagnifi N M, Alokali M S, Abd-Alranman S H, Draz H M, Yakout S M and Clerici M 2013
13	559	Polycyclic aromatic hydrocarbon exposure and pediatric astrima in children: a case-control study
14 15	560	Environmental health : a global access science source <b>12</b> 1
15 16	561	[37] Lin T-J, Guo Y L, Hsu J-C and Wang I-J 2018 2-Naphthol Levels and Allergic Disorders in Children
17	562	International journal of environmental research and public health <b>15</b>
18	563	[38] Cilluffo G et al 2022 Effects of Polycyclic Aromatic Hydrocarbons on Lung Function in Children
19	564	with Asthma: A Mediation Analysis International journal of environmental research and public
20	565	health 19
21	566	[39] Kapuci M, Ulker Z, Gurkan S and Alpsoy L 2014 Determination of cytotoxic and genotoxic effects
22	567	of naphthalene, 1-naphthol and 2-naphthol on human lymphocyte culture <i>Toxicology and</i>
23 24	568	industrial health <b>30</b> 82–9
25	569	[40] Carratt S A. Morin D. Buckpitt A R. Edwards P C and van Winkle L S 2016 Naphthalene
26	570	cytotoxicity in microsomal epoxide hydrolase deficient mice Toxicology letters <b>246</b> 35–41
27	570	[41] Holz $\Omega$ <i>et al</i> 2021 Breath volatile organic compounds and inflammatory markers in adult asthma
28	572	nations: nogative results from the ALLIANCE cohort The European respiratory journal 57
29	572	[42] Kamal E <i>et al</i> 2021 Virus-induced Volatile Organic Compounds Are Detectable in Exhaled Breath
30 21	575	during Pulmonany Infaction American journal of recritatory and critical care medicina <b>201</b> 1075
37	574	or
33	5/5	
34	576	[43] Wilkinson M, White I, Hamshere K, Holz O, Schuchardt S, Bellagambi F G, Lomonaco T, Blagini D,
35	5//	Di F F and Fowler S J 2021 The peppermint breath test: a benchmarking protocol for breath
36	578	sampling and analysis using GC-MS Journal of breath research <b>15</b>
37	579	[44] Filipiak W <i>et al</i> 2012 Dependence of exhaled breath composition on exogenous factors, smoking
38	580	habits and exposure to air pollutants <i>Journal of breath research</i> 6 36008
39 40	581	
41		
42	582	
43		
44		
45		
40 47		
48		
49		
50		
51		
52		
53 54		
54 55		
56		
57		
58		
59		
60		
		1/

#### Legends to figures

Figure 1. Study population. Breath VOCs were analyzed from 142 subjects. 40 subjects were sampled on two visits, which were at least one year apart. The Hannover site had a focus on wheezers and started the recruitment for VOC sampling later during the study. The one patient with asthma from Hannover was planned to be included as wheezer but the visit could not be scheduled before the 6<sup>th</sup> birthday, therefore based on the definition criteria, this subject was considered as child with asthma. 

Figure 2. Heatmap of VOC modules: VOCs are first clustered together based on pairwise Pearson correlations. A reliability score (i.e., the fraction of times that a given VOC is assigned to the same cluster) is calculated over 1,000 permutations of participants and is used to assign VOCs to modules. The color bars on the left side depict the module membership for each VOC (a full list is given in supplement table S4), and the coloring in the heatmap represents the reliability score of each VOC. 

Figure 3. Differences in the levels of naphthalene between groups. Median and interquartile ranges. Individual data is shown in grey open circles. \*\*\* p<0.001, \*\* p<0.01. 

 Page 19 of 21

# AUTHOR SUBMITTED MANUSCRIPT - JBR-101706.R1

Table 1. Demographics

<sup>5</sup> 605 6													
7			n	asthma	n	wheeze	n	healthy					
8 Q	Number of subjects	M/H	51	50/1	55	30 / 25	36	33 / 3					
10	Gender	female/male	51	16 / 35	55	20 / 35	36	12 / 24					
11	Age	years	51	12.9 ± 3.5***	55	5.7 ± 1.3***	36	9.7 ± 3.3					
12	Age at inclusion	years	51	10.8 ± 3.1	55	2.7 ± 1.5***	36	9.7 ± 3.3					
13	Atopy <sup>§</sup>	% pos.	46	85	43	58	35	37					
14	FeNO	ppb 🦱	44	24.7 (11.1;36.9)**	23	9.6 (5.1;19.9)	24	9.1 (5.6;20.2)					
15	FEV1	z-score	49	-0.53 (-1.09;0.23)***	48	-0.39 (-1.09;0.55)***	36	0.24 (-0.24;1.26)					
16	FEV1/FVC	z-score	49	- 0.57 (-1.34;0.15)***	47	- 0.28 (-1.18;0.87)	36	0.16 (-0.67;1.12)					
17	Blood leucocytes	cells/µL	46	7350 (6100;8300)	42	7500 (6400;9200)**	34	6675 (5500;7730)					
18	Blood eosinophils	cells/µL	46	358 (198;570)*	42	381 (260;582)**	34	201 (139;395)					
19	Blood neutrophils	cells/µL	46	3327 (2654;4300)	42	3430 (2603;4304)	34	3046 (2452;3696)					
20	Total IgE	kU/L	45	232 (162;562)**	41	111 (35;302)	34	110 (41;240)					
21	Asthma medication:												
22	SABA	n (%)	51	19 (37 %)	55	15 (27 %)							
25	Montelukast	n (%)	51	2 (4 %)	55	4 (7 %)							
24	ICS	n (%)	51	10 (20 %)	55	13 (24 %)							
26	LABA/ICS	n (%)	51	26 (51 %)	55	8 (15 %)							
27	wheezing episode (yes) <sup>\$</sup>	n (%)	51	13 (26 %)	55	25 (45 %)							
28	$\geq$ 1 exacerbation (yes) <sup>\$</sup>	n (%)	51	2 (4 %)	55	5 (9 %)							
29	M=Munich, H=Hannover												

M=Munich, H=Hannover

Mean  $\pm$  SD or median (25%;75% quartile) are presented. §: specific IgE >= 0,7 against at least 1/36 food- and aeroallergens.

Medication: number of children with respective treatment in the month before the VOC visit

Wheeze episode: symptoms of wheeze which required treatment with salbutamol for > 2 / 7 days

Exacerbation: wheeze episode which required treatment with systemic steroids or admission to hospital

\$: refers to 12 month prior to the VOC collection visit

\*\*\*p<0.001,

\*\*p<0.01,\*p<0.05

38 606

# AUTHOR SUBMITTED MANUSCRIPT - JBR-101706.R1

Table 2. Differences between healthy controls, asthmatic children, and children with wheeze

voc		*     Asthma vs.       프 명 이 오 오     Healthy								/or		61										/or		41			
				Wheez Heal	ize vs.		Food	Personal Care	Cleaning	Disinfectant	Air pollutant	νος		Asthma v	s. Healthy	Wheeze vs	. Healthy	ragrance / Flav	Food	Personal Care	Cleaning	Disinfectant	Air pollutant				
Lower in Diseased Patients		pMWU	pВH	pMWU	рВН							Increased in Diseased Patients		pMWU	рВН	pMWU	pBH										
unidentified C10H18 (a)	x	<0,001	<0,001	<0,001	0,007							Isoprene (b)		<0,001	<0,001	0,318	0,507										
Geranyl acetate	x	<0,001	0,003	0,003	0,035	x	x	x	×		1																
Pentadecane		<0,001	0,003	0,006	0,042	x	x	x				1-Phenoxypropan-2-ol	x	0,005	0,034	0,039	0,144			х	х	x					
Menthyl acetate	х	<0,001	0,005	0,001	0,028	×	х	x	×	х		Cycloheptasiloxane	x	0,021	0,093	0,004	0,037			х	х						
Decanoic acid methyl ester	x	0,001	0,009	0,002	0,033	×			x			Benzoic acid	x	0,022	0,093	<0,001	0,008	x	x	x	x						
Decanoic acid	x	<0,001	0,009	0,008	0,054	x	x	x	x			1-Nonene	x	0,068	0,179	0,004	0,037										
unidentified VOC (a)		<0,001	0,009	0,064	0,213							1,2-Propanediol	x	0,23	0,40	0,001	0,028	x	x	x	x	x	x				
Neryl acetate	х	0,002	0,019	0,038	0,144	х	х	х	x			2-Ethylhexanol		0,008	0,047	0,005	0,038	x	x				x				
2-Propanol		0,002	0,018	0,128	0,302	x	х	х	x	х		Limonene		0,051	0,146	0,001	0,028	x	x	x	x						
1-Decanol		0,002	0,020	<0,001	0,007	×	х	x	х	x		Naphthalene	х	<0,001	0,005	<0,001	0,007						x				
lonone		0,002	0,017	<0,001	0,007	x	x	x	x																		
Citronellol	x	0,001	0,015	0,002	0,033	x	х	x	х			Ethylbenzene	х	0,070	0,179	0,159	0,328						x				
b-Linalool	х	0,001	0,017	0,129	0,302	х	х	х	x	х		Benzene	x	0,046	0,138	0,344	0,537						x				
Decanal		0,003	0,023	0,025	0,120	x	x	x	х	x		p-/m-Xylene	х	0,144	0,297	0,151	0,328						x				
Linalyl acetate	х	0,005	0,031	0,158	0,328	х	х	х	x	х		o-Xylene	x	0,238	0,411	0,114	0,280						x				
Dioctyl ether		0,003	0,025	0,078	0,222	x		x	x			Toluene	x	0,113	0,260	0,036	0,144						x				
Camphene	×	0,002	0,018	0,057	0,201	х	х	х	x	х																	
Undecane	×	0,003	0,025	0,005	0,038	х	х	х				Hexanoic acid				0,002	0,034	x	x	x	x						
2,5-Dimethylfuran		0,251	0,425	0,004	0,037	x	x					Myrcen				0,005	0,038	x	x	x	x						
t-Butyl alcohol		0 115	0.261	0.003	0.034	×	×	×	×			The table contains all compounds which were different wheeze	nt betv	veen healthy	and asthma	a or healthy a	ind										
unidentified Terpene	x	0.030	0.107	0.004	0.038							Additional information was provided for other airpoll	utants	irrespective	of the level	of significanc	e										
3.7 - Dimethyloctan-1-ol	x	<0,001	0.005	0.003	0.034	x		x	x			(a) sign, correlation with e.g. Geranvacetate and othe	er lifest	vle VOCs sug	gests comm	non source											
Octanoic acid		0,007	0,043	0.385	0.570	x	х	x	х			(b) endogenous VOC. difference between groups mai	nlv due	to age depe	endency												
Nonane		0,007	0,043	0,033	0,141							Occurence and main use information based mainly or	n Europ	ean Chemica	al Agency (E	CHA)											
			•								-	pMWU: p-value uncorrected using non-parametric te	sting		5 71												
Hexanoic acid		0,401	0,554			x	x	x	x			pBH: p-value corrected for multiple testing (Benjamin	- ni-Hoch	berg)													
Myrcene	0,107			x	x	x	x			For more details on clusters refer to supplement table	e S4																

Page 21 of 21

AUTHOR SUBMITTED MANUSCRIPT - JBR-101706.R1

**Table 3.** Multivariable regression model investigating the association between module 6 and asthma or pre-school wheeze while controlling for known risk factors for asthma development

	Estimate	SE	Odds ratio	98% CI	p-value
Module 6	0.83	0.29	2.28	1.34 - 4.17	0.004
Atopy	1.96	0.53	7.08	2.62 - 21.0	<0.001
Age	-0.02	0.06	0.98	0.87 - 1.10	0.7
Gender (male)	-0.11	0.51	0.9	0.32 - 2.42	0.8
parental asthma	0.1	0.56	1.10	0.37 - 3.42	0.9
Eosinophils ≥470/µl	-0.87	0.59	2.39	0.79 - 8.05	0.14
Cigarette smoke exposure	-0.001	0.59	1.00	0.32 - 3.34	>0.9